Skip to main content
Signal8

Evofem Biosciences, Inc. (EVFM)

Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Evofem Biosciences, Inc. logo

Evofem Biosciences, Inc.

OTC:EVFMHealthcare
AH+0.00%$0.0043
Close$0.0043-28.93%
Mkt Cap$570K
EV-
Float132.53M
O/S132.53M
VOL2.7M sh
$ Vol$13K
RVOL24.51×
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution
Evofem Biosciences, Inc. logoOTC:EVFMAH$0.0043+0.00%

Evofem Biosciences, Inc. (EVFM) dilution facts from SEC filings

Snapshot as of Sep 30, 2026, built from 7 SEC filings.

Shelf registration
None on file in the filings reviewed
At-the-market (ATM) program
No active program in the filings reviewed
Warrants outstanding
15 warrant series recorded as outstanding
Most recent offering
None recorded in the filings reviewed

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro